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Adverse drug reactions (ADRs) remain associated with significant mortality. Delayed
hypersensitivity reactions (DHRs) that occur greater than 6 h following drug
administration are T-cell mediated with many severe DHRs now associated with
human leukocyte antigen (HLA) risk alleles, opening pathways for clinical prediction
and prevention. However, incomplete negative predictive value (NPV), low positive
predictive value (PPV), and a large number needed to test (NNT) to prevent one case
have practically prevented large-scale and cost-effective screening implementation.
Additional factors outside of HLA contributing to risk of severe T-cell-mediated DHRs
include variation in drug metabolism, T-cell receptor (TCR) specificity, and, most recently,
HLA-presented immunopeptidome-processing efficiencies via endoplasmic reticulum
aminopeptidase (ERAP). Active research continues toward identification of other highly
polymorphic factors likely to impose risk. These include those previously associated
with T-cell-mediated HLA-associated infectious or auto-immune disease such as Killer
cell immunoglobulin-like receptors (KIR), epistatically linked with HLA class I to regulate
NK- and T-cell-mediated cytotoxic degranulation, and co-inhibitory signaling pathways
for which therapeutic blockade in cancer immunotherapy is now associated with an
increased incidence of DHRs. As such, the field now recognizes that susceptibility is
not simply a static product of genetics but that individuals may experience dynamic
risk, skewed toward immune activation through therapeutic interventions and epigenetic
modifications driven by ecological exposures. This review provides an updated overview
of current and proposed genetic factors thought to predispose risk for severe T-cell-
mediated DHRs.
Keywords: delayed hypersensitivity, human leukocyte antigen, T-cell receptor, endoplasmic reticulum
aminopeptidase, genetic risk, immune checkpoint
INTRODUCTION
Adverse drug reactions (ADRs) are estimated as the fourth to sixth leading cause of death
(Dormann et al., 2000; Pouyanne et al., 2000; Miya et al., 2019). While the majority are classified
as type A, predictable based on drug pharmacology, the remainder are off-target type B ADRs
and inclusive of T-cell-mediated delayed drug hypersensitivity reactions (DHRs). While DHRs
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may elicit systemic effects, diverse clinical reactions also target
specific organs including drug-induced liver injury (DILI),
associated with nausea, fatigue, jaundice, and mortality up
to 9.4% (Leise et al., 2014). However, most often they
target skin, with presentation from mild rash (fixed drug
eruption, maculopapular exanthema) to life-threatening severe
cutaneous adverse reactions (SCARs) including Stevens-Johnson
Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) and drug
reaction with eosinophilia and systemic symptoms (DRESS)
(Peter et al., 2017). DRESS has a mortality up to 10%
(Kardaun, 2019; Wolfson et al., 2019) and is characterized by
widespread skin eruption, lymphadenopathy, fever, and multiple
organ involvement (Choudhary et al., 2013; Kardaun, 2019).
SJS and TEN are the same disease across a spectrum of
severity with the higher end of mortality (TEN) associated
with up to 50% death (Patel et al., 2013; Langley et al., 2018).
SJS/TEN is characterized by blistering and involvement of at
least two mucous membranes (Paulmann and Mockenhaupt,
2015; Miya et al., 2019; Zimmerman and Dang, 2020). Despite
clinical distinction, lack of mechanistic delineation has precluded
development of disease-specific treatment and prevention
strategies (Pavlos et al., 2015; Redwood et al., 2018). In recent
years many DHRs have been associated with strong human
leukocyte antigen (HLA) class I associations opening pathways
to prediction and prevention (Figure 1).




The HLA locus is highly polymorphic with >25,000 allelic
variants annotated (HLA.alleles.org). In 2002, Mallal
demonstrated carriage of HLA-B∗57:01 among 78% of HIV
patients with abacavir hypersensitivity, which is a well-
characterized systemic syndrome, opposed to just 2% of tolerant
patients (Mallal et al., 2002). A randomized double blind
clinical trial of real-time HLA-B∗57:01 screening versus abacavir
treatment without real-time screening showed a negative
predictive value (NPV) of 100% and a positive predictive
value (PPV) of 55% (Mallal et al., 2008), demonstrating that
HLA-B∗57:01 screening eliminates patch test positive abacavir
hypersensitivity. This PREDICT-1 study was the licensing study
upon which guideline-based HLA-B∗57:01 screening prior to
abacavir prescription was established.
Carbamazepine Hypersensitivity
In 2004, association between HLA-B∗15:02 and carbamazepine
(CBZ)-induced SJS/TEN in Taiwan was reported, which followed
the translational roadmap provided by abacavir such that 0/4120
Taiwanese HLA-B∗15:02-negative patients developed SJS/TEN
after CBZ exposure (Chung et al., 2004). Pre-prescription HLA-
B∗15:02 screening for CBZ is now active in Hong Kong,
Singapore, and Thailand where there is high allelic prevalence
(FerrellJr., and McLeod, 2008). However, HLA-B∗15:02 is
FIGURE 1 | The cellular role of genetic risk factors defined and proposed for
development of delayed drug hypersensitivity reactions. Drug antigen may
bind directly to (i) specific human leukocyte antigen (HLA) molecules on the
surface of antigen-presenting cells (APC) for recognition by corresponding (ii)
T-cell receptors (TCRs). Alternatively, drug may undergo (iii) metabolism and
cellular processing by (iv) endoplasmic reticulum aminopeptidase (ERAP), with
the peptide products then presented by the risk HLA molecule for TCR
recognition. (v) Distinct killer-cell immunoglobulin-like receptors (KIR),
expressed on both T-cell and Natural Killer (NK) cells, also show specificity for
HLA-antigen interaction, which may regulate cytotoxic degranulation. (vi)
Co-signaling pathways also regulate T-cell activation, with overall co-inhibition
or co-stimulation leading to (vii) cytokine release and respective tolerance with
T-regulatory cell (Treg)-induced immunosuppression or inflammation and
cytotoxic degranulation, respectively.
expressed in <1% of patients of European or African ancestry
despite global disease burden, restricting universal screening
and inferring that different HLA alleles drive reactions in
different populations (Karnes et al., 2019). Indeed, multiple alleles
are now associated with CBZ-SCAR in distinct populations,
with HLA-A∗31:01 associated with DRESS in Europeans and
Chinese, but not SJS/TEN (McCormack et al., 2011; Genin et al.,
2014), highlighting propensity for distinct alleles to define risk
for specific reactions. Most recently, Nicoletti reported HLA-
A∗31:01 as a strong risk factor broadly across CBZ-induced
SCAR and DILI in Europeans (Nicoletti et al., 2019) while
Mockenhaupt described an HLA-B∗57:01 association for CBZ-
SJS/TEN in Europeans (Mockenhaupt et al., 2019). These studies
demonstrate that HLA restriction may be complex, with influence
from multiple alleles restricted to antigen, reaction phenotype,
and population (Table 1).
HLA AND ITS USE IN CLINICAL
PRACTICE
HLA-B∗58:01 and Allopurinol-DRESS
Other strong HLA associations have been described with near-
complete NPV for WHO essential medicines, the most effective
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TABLE 1 | HLA risk alleles associated with delayed type drug hypersensitivity reactions.
Drug HLA risk allele Reaction Ethnic population PPV (NPV) References
Abacavir B*57:01 HSS African 50 (100) Saag et al., 2008
Caucasian 50 (100) Mallal et al., 2002, 2008
Hispanic 96 (60) Sousa-Pinto et al., 2015
Acetazolamide B*59 SJS/TEN Korean Her et al., 2011
Allopurinol B*58:01 DRESS, SJS/TEN Caucasian Jarjour et al., 2015
DRESS Caucasian (Portuguese) Gonçalo et al., 2013
DRESS, SJS/TEN Han Chinese 3 (100) Chiu et al., 2012
DRESS, SJS/TEN Korean 2.06 (99.98) Kang et al., 2011
DRESS Thai 8.26 (100) Sukasem et al., 2016
MPE, SJS/TEN Japanese Kaniwa et al., 2008; Jarjour
et al., 2015
MPE Thai 5.13 (99.90) Sukasem et al., 2016
SJS/TEN Caucasian Lonjou et al., 2008; Yu
et al., 2017
Thai 10.48 (100) Sukasem et al., 2016
C*03:02 DRESS, SJS/TEN Korean 1.77 (99.98) Kang et al., 2011
A*33:02 DRESS, SJS/TEN Korean 0.8 (99.96) Kang et al., 2011
Amoxicillin-clavulanate DRB1*15:01 DILI Caucasian Lucena et al., 2011
Azathioprine DQA1*02:01 Pancreatitis Caucasian Heap et al., 2014
DRB1*07:01 Heap et al., 2014
Benznidazole A*11:01 MPE, DRESS Bolivian 100 (70) Balas et al., 2020
A*29:02 100 (70)
A*68 48 (84)
Carbamazepine A*24:02 SJS/TEN Han Chinese Shi et al., 2012
A*31 DRESS, SJS/TEN, MPE Japanese Niihara et al., 2012
A*31:01 DRESS Caucasian 0.77 (99.98) Genin et al., 2014
Han Chinese 0.67 (99.97) Genin et al., 2014
SJS/TEN Caucasian McCormack et al., 2011
Han Chinese Genin et al., 2014
DRESS, SJS/TEN Korean Kim et al., 2011b
SCAR, DILI Caucasian Nicoletti et al., 2019)
B*15:02 SJS/TEN Han Chinese 2.24 (99.94) Tangamornsuksan et al.,
2013; Genin et al., 2014
Indian Mehta et al., 2009
Korean Tangamornsuksan et al.,
2013
Malaysian Tangamornsuksan et al.,
2013
Thai Tangamornsuksan et al.,
2013; Sukasem et al., 2018
Taiwanese 93.6 (100) Chung et al., 2004
B*15:11 SJS/TEN Han Chinese Shi et al., 2012
Asian 43.8 (95.1) Wang et al., 2017
B*15:21 SJS/TEN Thai Sukasem et al., 2018
SJS/TEN Filipino 1.03 (87.5) Capule et al., 2020
B*51:01 DRESS, MPE Han Chinese Wang et al., 2017
B*57:01 SJS/TEN Caucasian Mockenhaupt et al., 2019
B*58:01 DRESS, MPE Asian 90.4 (37) Wang et al., 2017;
Sukasem et al., 2018
DRB1*14:05 MPE Han Chinese Li et al., 2013
Co-trimoxazole B*15:02, C*08:01 SJS/TEN Thai Sukasem et al., 2020
B*13:01 DRESS
Dapsone B*13:01 DRESS Chinese 7.8 (99.8) Zhang et al., 2013
(Continued)
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TABLE 1 | Continued
Drug HLA risk allele Reaction Ethnic population PPV (NPV) References
DRESS, SJS/TEN Thai Tempark et al., 2017
DRESS Taiwanese Chen et al., 2018
Malaysian
Flucloxacillin B*57:01 DILI Caucasian 0.12 (99.99) Daly et al., 2009
Isoxicam, Piroxicam A*02 SJS/TEN Caucasian Roujeau et al., 1987
B*12
Lamotrigine A*02:07 MPE, DRESS, SJS/TEN Thai Koomdee et al., 2017
A*24:02, C*01:02 MPE Korean Moon et al., 2015
A*30:01 Han Chinese Li et al., 2013
B*13:02
A*33:03 Thai Koomdee et al., 2017
B*44:03
A*31:01 DRESS, SJS/TEN Korean Kim et al., 2017
A*68:01 DRESS, SJS/TEN Caucasian Kazeem et al., 2009
B*15:02 SJS/TEN Han Chinese Cheung et al., 2013
DRESS, SJS/TEN, MPE Thai Koomdee et al., 2017
SJS/TEN Iranian 78.57 (56.41) Sabourirad et al., 2020
B*38 SJS/TEN Caucasian Lonjou et al., 2008




Methazolamide B*59:01 SJS/TEN Japanese Nakatani et al., 2019
Korean Tangamornsuksan and
Lohitnavy, 2019
Han Chinese 100 (96.8) Yang et al., 2015;
Tangamornsuksan and
Lohitnavy, 2019
Minocycline B*35:02 DILI Caucasian (Urban et al., 2017)
Nevirapine Cw4 DRESS Han Chinese Gao et al., 2012
C*04:01 SJS/TEN Malawian 2.6 (99.2) Carr et al., 2013, 2017
C*08 DRESS Japanese Gatanaga et al., 2007
C*08:02, B*14:02 DRESS Caucasian (Sardinian) Littera et al., 2006
B*35:05 Skin Rash Thai Chantarangsu et al., 2009
DRB1*01:01 DRESS Caucasian Martin et al., 2005
Oxcarbazepine A*03:01 MPE Uighur Chinese Zhao et al., 2020
B*07:02
B*15:02 MPE, SJS/TEN Han Chinese Hung et al., 2010
B*38:02 MPE Lv et al., 2013
Oxicams B*73 SJS/TEN Caucasian Lonjou et al., 2008
Phenobarbital B*51:01 SJS/TEN Japanese Kaniwa et al., 2013
Phenytoin B*13:01 SJS/TEN East Asian Su et al., 2019
B*15:02 SJS/TEN East Asian Su et al., 2019
Han Chinese (Cheung et al., 2013
Malaysian (Chang et al., 2017
Thai 33 (100) Locharernkul et al., 2008
B*15:13 DRESS, SJS/TEN Malaysian Chang et al., 2017
B*56:02 SJS/TEN Thai Tassaneeyakul et al., 2016
DRESS Australian Aboriginal Somogyi et al., 2019
Cw*08:01 SJS/TEN Han Chinese Hung et al., 2010
DRB1*16:02
Raltegravir B*53:01 DRESS African Thomas et al., 2017
Strontium Renalate A*33:03 SJS/TEN Han Chinese Lee et al., 2016
(Continued)
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TABLE 1 | Continued
Drug HLA risk allele Reaction Ethnic population PPV (NPV) References
B*58:01
Sulfamethoxazole A*29 SJS/TEN Caucasian Roujeau et al., 1987
A*30 FDE Turkish Özkaya-Bayazit and Akar,
2001
A*30-B*13-C*06
A*11:01 SJS/DRESS Japanese Nakamura et al., 2020
B*13:01 SCAR Asian 4.05 (99.92) Wang et al., 2020
DRESS 3.64 (99.92)
B*14:01 DILI European American Li et al., 2020
B*35:01 African American Li et al., 2020
B*44 (B12 serotype) SJS/TEN Caucasian Liang et al., 2013
B*38 SJS/TEN Caucasian Lonjou et al., 2008
DR*07
Sulfasalazine B*13:01 DRESS Han Chinese Yang et al., 2014
Ticlopidine A*33:03 DILI Japanese Hirata et al., 2008
Terbinafine A*33:01 DILI Caucasian Fontana et al., 2018
Vancomycin A*32:01 DRESS Caucasian Konvinse et al., 2019
Zonisamide A*02:07 SJS/TEN Japanese Kaniwa et al., 2013
References included were studies associated with clinically defined DHR. DILI, drug-induced liver injury; DRESS, drug reaction with eosinophilia and systemic symptoms;
FDE, fixed drug eruption; HSS, hypersensitivity syndrome; MPE, maculopapular eruption; NPV, negative predictive value; PPV, positive predictive value; SCAR, severe
cutaneous adverse reaction; SJS/TEN, Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. NPV and PPV are based on case-control studies and require ongoing
validation and thus subject to change.
and safe drugs to meet the most important needs, such as
allopurinol, dapsone, and vancomycin (WHO, 2021). Allopurinol
is used for treatment of gout but is also the most prevalent drug
cause of DRESS in the FDA Adverse event reporting system
(Bluestein et al., 2021). In 2005, HLA-B∗58:01 was associated
with allopurinol-induced SCAR with 100% NPV in Southeast
Asians (Hung et al., 2005). Subsequent studies confirmed risk
in cohorts from Europe (Lonjou et al., 2008), Japan (Kaniwa
et al., 2008), Thailand (Yu et al., 2017), South Korea (Kang
et al., 2011), and Portugal (Gonçalo et al., 2013), but, as with
CBZ, comparative strength of association and allelic frequency
is not replicated and is far lower in Europeans (Génin et al.,
2011). Currently, where patients are known to be HLA-B∗58:01+,
the European Medicines Agency advises clinicians to avoid
allopurinol and screening is recommended in Korean, Thai,
or Han Chinese patients (Ke et al., 2017). However, recent
analysis in the UK defined the number needed to test (NNT)
as 11,286, leading the panel to advise against routine screening
(Plumpton et al., 2017).
HLA-B∗13:01 and Dapsone-SCAR
The antibiotic dapsone is predominantly associated with
treatment of leprosy (Wolf et al., 2002). In 2013, HLA-B∗13:01
was described with 99.8% NPV and 7.8% PPV as a risk factor
among Chinese patients for dapsone hypersensitivity (Zhang
et al., 2013). While prevalent in Chinese and Indian populations,
HLA-B∗13:01 is comparatively absent among Europeans and
Africans. HLA-B∗13:01 risk is now confirmed for dapsone-SCAR
in Thailand (Tempark et al., 2017) and research has modeled drug
interaction within the HLA binding site (Watanabe et al., 2017).
Most recently, Chen expanded HLA-B∗13:01 risk to patients from
Malaysia and Taiwan (Chen et al., 2018), and Zhao identified
dapsone-responsive HLA-B∗13:01-restricted CD8+ T-cells in
patients (Zhao et al., 2019).
HLA-A∗32:01 and Vancomycin-DRESS
Vancomycin, a front-line treatment for beta-lactam-resistant
infections (Rybak et al., 2009; Frymoyer et al., 2013; Moore
et al., 2020), is the most common antibiotic instigator of DRESS
(Wolfson et al., 2019). In 2019, Konvinse published strong
association between HLA-A∗32:01 and vancomycin-DRESS
determining that 20% of HLA-A∗32:01+ patients would develop
the disease (Konvinse et al., 2019). With a European prevalence of
6.8%, they predicted the NNT as just 75 and have since developed
an HLA-A∗32:01-specific, cost-effective real-time PCR screen
(Rwandamuriye et al., 2019). In 2020, Nakkam described cross-
reactivity with an alternate glycopeptide antibiotic, teicoplanin,
in 16% of HLA-A∗32:01+ vancomycin-DRESS patients predicted
by a shared class II HLA haplotype (Nakkam et al., 2020).
These data implicate risk alleles with influence not simply
to dictate predisposition but with ramifications for ongoing
treatment. Importantly, while predictive values defined by limited
case-control studies may not be indicative of risk in the
underlying population, warranting caution, in vitro assays have
functionally confirmed that HLA risk restricted drug-specific
T-cell activation for abacavir, CBZ, allopurinol, dapsone, and
vancomycin (Chessman et al., 2008; Wei et al., 2012; Yun et al.,
2014; Zhao et al., 2019; Nakkam et al., 2020).
RECENTLY REPORTED HLA
ASSOCIATIONS (2019-)
Single HLA associations up until 2019 have been
extensively reviewed (White et al., 2015; Karnes et al., 2019;
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Oussalah et al., 2020). Since then, further advancement in
sequencing platforms has been providing increased resolution
that has enabled discovery of novel HLA associations (LaHaye
et al., 2016; van der Ven et al., 2018; Giannopoulou et al.,
2019; Mimori et al., 2019). In 2019, Nakatani reported a
Japanese association between SJS/TEN, HLA-A∗02:06:01, and
cold medicines containing non-steroidal anti-inflammatories
(Nakatani et al., 2019). Furthermore, Tangamornsuksan
reported an association between methazolamide-induced
SJS/TEN and HLA-B∗59:01 in Koreans and Han Chinese
(Tangamornsuksan and Lohitnavy, 2019). In 2020, within a
Thai HIV cohort, Sukasem reported an association between
co-trimoxazole-induced DRESS with HLA-B∗13:01 and SJS/TEN
with HLA-B∗15:02 and HLA-C∗08:01 (Sukasem et al., 2020).
Furthermore, MPE and DRESS resulting from benznidazole was
associated with HLA-A∗68, A∗11:01, and A∗29:02 in Bolivian
patients with Chagas disease (Balas et al., 2020). Most recently,
Zhao reported an association between oxcarbazepine-induced
MPE and HLA-A∗03:01 and HLA-B∗07:02 in patients of Uighur
Chinese ethnicity (Zhao et al., 2020). Moreover, HLA associations
have also been reported for herbal medicines including green tea
(Hoofnagle et al., 2020) and polygonum multiflorum with HLA-
B∗35:01 (Li et al., 2019). These studies provide a glimpse into the
recent progress toward risk prediction specific to populations,
yet a significant hurdle remains risk discovery in minority groups
for whom access to large cohorts for traditional population
studies is nearly impossible. One strategy is to maximize utility
of international SCAR registries where careful patient matching
for drug, reaction phenotype, and ethnicity may provide means
to explore shared risk (Somogyi et al., 2019). Indeed, Somogyi
identified three patients of Australian Indigenous ethnicity
with phenytoin-DRESS sharing HLA-B∗56:02 (Somogyi et al.,
2019). Critically, HLA-B∗56:02 frequency ranges up to 19% in
this population but is absent from the predominant Australian
European populace, highlighting utility of detailed biobanking
with functional validation of proposed risk alleles (Monshi et al.,
2013; Pan et al., 2019). Another possibility is the likelihood
that alleles with shared specificities drive response to the same
drug, as for nevirapine (Chantarangsu et al., 2009; Carr et al.,
2013). Here, association with HLA-C∗04 across ethnicities is
driven by a unique F pocket motif that determines similar
binding specificity for HLA-C∗04:01 with HLA-C∗05:01 and
HLA-C∗18:01, dominant in Hispanics and Africans, respectively
(Pavlos et al., 2017). The ability to design HLA crystal structures
combined with HLA binding algorithms provides a functional
bridge to understand whether proposed antigen binds to diverse
alleles (Pavlos et al., 2017). Nonetheless, HLA is not the sole
requirement for T-cell activation and other parameters are
proposed to retain the HLA-restricted “positive predictive gap.”
T-CELL RECEPTORS PROVIDE
SPECIFICITY FOR RECOGNITION OF
RISK HLA-ANTIGEN COMPLEX
Antigenic peptides bound to HLA must contact the T-cell
receptor (TCR) to trigger T-cell activation (Figure 1). Each
individual’s TCR repertoire comprises a diverse blend of public
and private TCRs, which, through prior antigen exposure, may be
uniquely distributed in tissues (Robins et al., 2010). A polyclonal
response is well documented for abacavir (Redwood et al., 2019).
This is in keeping with the altered peptide repertoire hypothesis
suggesting that abacavir binds within the F pocket of the HLA-
B∗57:01 peptide binding groove altering its peptide specificity
and the repertoire of self-peptides recognized as immunogenic
(Illing et al., 2012). Polyclonal response is also observed during
CDR3 spectratyping after the in vitro priming of naïve T-cells
to the immunogenic drug metabolite sulfamethoxazole-nitroso
(SMX-NO) (Gibson et al., 2017). Here the authors implicate the
high protein reactivity of SMX-NO thought to drive formation
of multiple haptens, each with potential to produce a diverse
array of antigenic peptides. However, early work by Nassif reports
predominant expression of Vβ 13.1 and 14 on T-cells in the blister
of such patients, suggesting that early response in tissue is driven
by more select, dominant clonotypes (Nassif et al., 2002). In 2019,
Pan reported dominant single, public “VFDNTDKLI” TCRα
CDR3 and “ASSLAGELFF” TCRβ CDR3 in HLA-B∗15:02+
patients with CBZ hypersensitivity, rare in blood but dominantly
expressed in blister (Pan et al., 2019). The dominant TCR
was identified on T-cells expressing granulysin, a key cytotoxic
mediator with precedent in eliciting tissue damage (Pan et al.,
2019). Furthermore, the complete TCR blueprint provided by
single-cell sequencing was synthetically reconstructed and shown
to trigger T-cell activation specific to CBZ and HLA-B∗15:02.
Preferential TCR expansion has also been described in blister
during HLA-B∗58:01-associated allopurinol-SCAR (Chung et al.,
2015). While further studies are warranted, those described begin
to elucidate the specificity of a single dominantly expanded TCR
to drive early response in the tissue of HLA-predisposed patients.
ERAP VARIANTS SKEW THE
HLA-RESTRICTED IMMUNOPEPTIDOME
Although drug-protein conjugates are found at similar levels in
allergic and tolerant patients (Park et al., 1998; Sullivan et al.,
2015), the downstream impact of N-terminal peptide trimming
that shapes the HLA-presented immunopeptidome has remained
undefined. This process is performed by endoplasmic reticulum
aminopeptidases (ERAPs) 1 and 2 (Serwold et al., 2001; Chang
et al., 2005; Figure 1) for which polymorphic variants alter
susceptibility and outcome to autoimmune disease and viral
infections with HLA class I-restricted etiologies (Evans et al.,
2011; Guerini et al., 2012; Biasin et al., 2013; Fruci et al., 2014;
Reeves and James, 2015; Saulle et al., 2019; Vidal-Castiñeira
et al., 2020). Specifically, distinct ERAP1 allotypes skew the
HLA-class I-expressed immunopeptidome during infectious
disease, where hypoactive allotypes result in longer sub-dominant
peptides that impair CD8+ T-cell response (Kemming et al.,
2019). Intriguingly, peptides with aromatic or hydrophobic
C-terminal amino acids are favored by ERAP1 for efficient
N-terminal trimming and treatment of cells with abacavir alters
the self-peptide preference toward the same amino acids (Chang
et al., 2005; Ostrov et al., 2012). In 2020, Pavlos identified
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ERAP1 as a novel predictor of abacavir tolerance among HLA-
B∗57:01+ patients. Tolerant patients were significantly more
likely to express ERAP1 hypoactive allotypes with reduced
trimming efficiency compared to hypersensitive patients (Pavlos
et al., 2020). While yet to transverse other drugs, the epistatic
relationship between HLA and ERAP raises intrigue to the
influence of other such genes. One such entity is the highly
polymorphic Killer-cell Immunoglobulin-like receptors (KIRs)
expressed on T-cells and Natural Killer (NK) cells (Mingari
et al., 1997; LeMaoult et al., 2005), with both cell types reporting
the predominant infiltrate of in SJS/TEN blister (Chung and
Hung, 2010). HLA alleles are the distinct ligands for KIRs that
regulate cytotoxic degranulation in a complex interaction with
sensitivity to the presented peptide via overlapped TCR binding
(Mandelboim et al., 1997; Boyington and Sun, 2002; Thananchai
et al., 2007; Fadda et al., 2010; Figure 1). Notably, specific
KIR have been associated with progression of HLA-restricted
infectious disease (Bellón, 2019). Description by Fasbender of
the induction of NK-activating ligands on hepatocytes after
drug exposure, driving NK-mediated cytotoxicity, spurs interest
given that T-cells in the blood of SJS/TEN patients overexpress
KIR2DL2 and KIR2DL3 (Morel et al., 2010; Fasbender et al.,
2020). With yet unreported genetic or functional assessment,
studies are warranted to understand the combined influence of
these interactions.
THE LIMITED ROLE OF ALTERED DRUG
METABOLISM IN FORMATION OF
IMMUNOGENIC MOIETIES
Drugs lacking protein reactivity may directly activate T-cells
(Schnyder et al., 1997; Zanni et al., 1997; Naisbitt et al.,
2003). However, metabolic detoxification pathways form protein-
reactive metabolites, also reported to activate drug-specific
T-cells (Naisbitt et al., 2001; Sullivan et al., 2015; Figure 1).
Metabolism is highly varied due to polymorphic enzymes, with
cytochrome P450 (CYP450) enzymes responsible for 90% of
drug metabolism (Lynch and Price, 2007) and for which allelic
variants are described from poor to ultrarapid metabolisers
(Zanger and Schwab, 2013). While metabolic activity of skin
is considered limited (Sharma et al., 2019), keratinocytes show
capacity to metabolize and present drug-derived antigens (Reilly
et al., 2000; Roychowdhury and Svensson, 2005). Several studies
now investigate metabolic variants associated with DHR, most
notably for phenytoin, predominantly oxidized to an inactive
metabolite by CYP2C9 with minor contribution by CYP2C19.
Genetic analyses show that CYP2C9∗2 and CYP2C9∗3 low
function variants extend exposure to the immunogenic parent
drug (Aynacioglu et al., 1999; Silvado et al., 2018). Specifically,
CYP2C9∗3 is associated with SJS/TEN in both Han Chinese
(Chung et al., 2014) and Thai (Suvichapanich et al., 2015;
Tassaneeyakul et al., 2016). In addition, CYP2C19∗3 is associated
with phenytoin-DRESS in Thai (Yampayon et al., 2017). In
2019, Su et al. (2019) published on the utility of combined
risk HLA and CYP2C9∗3 genetic testing in Asian populations
to prevent phenytoin hypersensitivity. It is now advised that
physicians reduce the starting dose by 25% for patients
classed as intermediate metabolizers, defined by CYP2C9∗1/∗3
and CYP2C9∗1/∗2 carriage (Caudle et al., 2014). Metabolic
variation is also associated with DHR driven by nevirapine,
hydroxylated by CYP2B6. Loss of functional alleles CYP2B6∗6
and CYP2B6∗18 are associated with increased susceptibility
for nevirapine-SJS/TEN, with the ∗18 variant only observed
in patients of African ancestry (Ciccacci et al., 2013; Carr
et al., 2014). A handful of other associations are explored by
Pirmohamed and were not significant upon multiple-testing
correction (Pirmohamed et al., 2000); thus, most data to date
implicate only a minor role for metabolic variation in DHR.
THE INFLUENCE OF INFECTIOUS
DISEASE
There are three main aspects to consider for the impact of
infectious disease on DHR. The first aspect is the effect of
cumulative drug exposure in cohorts where long-term exposures
are driven by repeat infection like antibiotic hypersensitivity in
patients with cystic fibrosis (CF). Indeed, CF patients are far more
likely to develop an allergy to beta-lactams than patients without
(Burrows et al., 2007; Wright et al., 2018); thus, it is possible
that repeat high dosing and antigen accumulation contributes
to risk. Second is the potential for disease-associated immune
dysregulation to heighten allergic susceptibility. An example is
the reduced DHR incidence in HIV patients following initiation
of successful highly active antiretroviral therapy, which controls
viral progression, preventing deterioration of immune function
(Coopman et al., 1993; Li et al., 1998). Similarly, studies show
that CF patients have dysfunctional antiviral T-cell responses
(Hubeau et al., 2004). Indeed, toll-like receptor 4, which mediates
inflammatory cytokine expression, is reduced in CF airway cell
lines (John et al., 2010; Keiser et al., 2015). Interestingly, cytokine
variants predispose to DHRs such as liver injury: IL10-592 AA
and IL10-819 TT are associated with docetaxel-induced liver
injury, and polymorphism-380G/A in TNF−α is associated with
hepatitis induced by antituberculosis drugs (Kim et al., 2011a;
Liang et al., 2013; Figure 1). Evidence suggests that drug antigens
may mount response in tissue through pre-existing antiviral
T-cells in a heterologous immunity model (Descamps et al.,
2003; Mitani et al., 2005). Functional evidence is based on
work by Lucas who showed that all drug-naive HLA-B∗57:01+
individuals have T-cells responsive to abacavir (Lucas et al., 2015;
Gibson et al., 2017). Such reactive promiscuity across all healthy
donors implicates cross-reactivity with common broad-exposure
pathogens (Smith et al., 2016).
THE INFERRED ROLE OF EPIGENETIC
RISK
It is now well established that epigenetic modifications
to open or close the transcriptional template of genes
impacts immunological processes (North and Ellis, 2011;
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Moggs et al., 2012). Epigenetic influence is environmental with
documented effects from diet, viral exposures, and pollution
driving distinguishable differences in immune status; thus, it
may drive not only inter-individual but also intra-individual
risk over time, proposing dynamic susceptibility. Indeed, Nadeau
describes hypermethylation of the FOXP3 locus affecting Treg
function and asthma severity in patients who live in areas with
higher air pollution (Nadeau et al., 2010). Evidence now suggests
that epigenetic effects may be multi-generational, with lead
exposure and subsequent DNA methylation of fetal germ cells in
grandparents traced through to grandchildren (Sen et al., 2015).
While likely, epigenetic influence has yet to be directly inferred
upon susceptibility to DHR, but there is some initial evidence.
In 2018, Cheng published that risk of allopurinol-induced SCAR
was attributed to variants of HCP5, PSORS1C1, TSHZ2, and
NOTCH4. Although distinct polymorphisms and thus genetic
variants, intriguingly NOTCH4 and TSHZ2, were included as
genes that presented as highly differentially methylated, a form
of epigenetic regulation (Cheng et al., 2017). Furthermore,
Monroy-Arreola demonstrated upregulation of microRNA-21, -
18, and -155 in drug-specific CD4+ T-cells from hypersensitive
patients (Monroy-Arreola et al., 2018). While microRNA may
regulate post-transcriptional gene expression, others bind to
control regulators of epigenetic modification including DNA
methyltransferases (Sato et al., 2011).
DYNAMIC DYSREGULATION IMPOSED
BY IMMUNE CHECKPOINTS SPANS
GENETIC AND THERAPEUTIC RISK
Immune checkpoints regulate T-cell activation to prevent
uncontrolled activation. This complex process is the summation
of varied co-stimulatory and opposingly co-inhibitory pathways
(Figure 1). Intriguingly, polymorphic variants of checkpoints are
linked to numerous autoimmune diseases including rheumatoid
arthritis (Kong et al., 2005), multiple sclerosis (Kroner et al.,
2005), and ankylosing spondylitis (Kantarci et al., 2003). While
allelic influence is yet to be translated to risk for DHR,
mechanistic studies have demonstrated the impact of blocking
programmed death-1 (PD-1) or cytotoxic lymphocyte antigen-4
(CTLA4) axes to enhance naive T-cell priming to drug antigens
(Gibson et al., 2014, 2017). Checkpoint inhibition is now widely
adopted in cancer immunotherapy to re-invigorate anti-tumor
T-cell responses, but dysregulation is not antigen-specific and
immune-mediated ADR are common (Naidoo et al., 2015; Saw
et al., 2017; Lomax et al., 2019). While reactions are varied
and typically reported as enhanced immunogenicity to self
(Mangan et al., 2020), emerging small cohort studies describe
a high incidence of DHR in immune checkpoint inhibitor-
treated patients (Imafuku et al., 2017; Ford et al., 2018). These
studies remain only clinical observations and distinct checkpoint
alleles have not been identified in genome-wide association
studies; however, given the influence of multiple, counteracting
co-signaling pathways, it may be that single variants have
a low individual effect for which the previous studies have
been underpowered. Further study is now warranted to define
association with a greater risk of drug hypersensitivity reactions.
SUMMARY
Given a lack of a single HLA allele to provide complete PPV, other
risk factors must further restrict response and recent advances
have detailed (i) application of single-cell sequencing to define the
HLA-restricted dominant TCR driving early response in tissue
and (ii) the impact of ERAP variants to skew immunodominant
peptide presentation. Intriguingly, other proposed risk factors
such as checkpoint receptors span genetic and epigenetic
risk, with expression subject to environmental or therapeutic
pressures, implicating highly dynamic risk. Strategies are now
needed to identify risk alleles in minority populations where
large clinical cohorts are impossible to obtain. The availability
of multi-omic approaches offers opportunity to merge high-
resolution genotyping with single-cell phenotyping to tease out
more complex risk signatures that may also enable cost-effective
patient screening.
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